US OptionsDetailed Quotes
CRVS241220P18000
- 14.60
- +0.99+7.27%
15min DelayTrading Dec 19 09:52 ET
14.60High14.60Low
14.60Open13.61Pre Close1 Volume1 Open Interest18.00Strike Price1.46KTurnover0.00%IV25.93%PremiumDec 20, 2024Expiry Date13.41Intrinsic Value100Multiplier1DDays to Expiry1.19Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.34Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Corvus Pharmaceuticals Stock Discussion
Sign in to post a comment
$Nukkleus (NUKK.US)$
day 2, though im making 1k+ from this NUKE everyday… im just covering loss from pharma… never gonna touch meds again else wld be up 6k+ hahahaha
day 2, though im making 1k+ from this NUKE everyday… im just covering loss from pharma… never gonna touch meds again else wld be up 6k+ hahahaha
3
3
$Corvus Pharmaceuticals (CRVS.US)$
why everyone are leaving? i thought this is a promising clinical sign???
why everyone are leaving? i thought this is a promising clinical sign???
4
$Corvus Pharmaceuticals (CRVS.US)$ Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile
Data includes complete results from cohort 1 and initial results from cohort 2
Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million
Company to host conference call and webca...
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile
Data includes complete results from cohort 1 and initial results from cohort 2
Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million
Company to host conference call and webca...
2
6
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Quantum-Si (QSI.US)$ $Linkage Global (LGCB.US)$ $Corvus Pharmaceuticals (CRVS.US)$ $Allakos (ALLK.US)$ $Richtech Robotics (RR.US)$ $CERo Therapeutics (CERO.US)$ $The Glimpse (VRAR.US)$ $Zeo Energy (ZEO.US)$ $Rezolve AI (RZLV.US)$ $Tonix Pharmaceuticals (TNXP.US)$ $Nukkleus (NUKK.US)$ $1847 Holdings (EFSH.US)$ $ParaZero Technologies (PRZO.US)$ $Vast Renewables (VSTE.US)$
📊⚡️📊
📊⚡️📊
15
2
$Corvus Pharmaceuticals (CRVS.US)$ Corvus Pharmaceuticals to Announce Interim Data From Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
2
NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 ...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 ...
58
18
2
$Corvus Pharmaceuticals (CRVS.US)$
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe ...
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe ...
1
2
$Corvus Pharmaceuticals (CRVS.US)$ Any news for this >10 % drop in 5 days?
$Corvus Pharmaceuticals (CRVS.US)$
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Corvus Pharmaceuticals announced new preclinical data showing that soquelitinib, their lead ITK inhibitor, could potentially prevent lung damage, inflammation, and pulmonary hypertension caused by systemic sclerosis. The study used Fra-2 transgenic mice, which mirror human systemic sclerosis features. After seven weeks of oral soquelitinib...
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Corvus Pharmaceuticals announced new preclinical data showing that soquelitinib, their lead ITK inhibitor, could potentially prevent lung damage, inflammation, and pulmonary hypertension caused by systemic sclerosis. The study used Fra-2 transgenic mice, which mirror human systemic sclerosis features. After seven weeks of oral soquelitinib...
1
$Corvus Pharmaceuticals (CRVS.US)$
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
Corvus Pharmaceuticals (NASDAQ: CRVS) presented new data at SITC's 39th Annual Meeting showing ciforadenant's potential to overcome resistance to anti-PD1 immunotherapy in metastatic castration resistant prostate cancer (mCRPC). The research, selected as a Top 100 abstract, identified SPP...
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
Corvus Pharmaceuticals (NASDAQ: CRVS) presented new data at SITC's 39th Annual Meeting showing ciforadenant's potential to overcome resistance to anti-PD1 immunotherapy in metastatic castration resistant prostate cancer (mCRPC). The research, selected as a Top 100 abstract, identified SPP...
2
No comment yet
seer84 OP : Med stocks are total scam
151766892 : fake Israel
scam stay away
seer84 OP 151766892 : The only Israel war winner is right here